BACKGROUND: The impact of impaired pulmonary function on the clinical outcome of small cell lung cancer (SCLC) has not been examined. The objectives of this study were to compare the clinical characteristics and prognosis of SCLC patients with and without impaired pulmonary function and investigate predictors related to the pulmonary function of mortality in SCLC patients. METHODS: This is a retrospective multicenter study performed between January 2011 and December 2015. In all, 170 SCLC patients that were treated with chemotherapy and/or radiotherapy and had a pulmonary function test (PFT) were enrolled. Patients were divided into the chronic obstructive pulmonary disease (COPD) group and the non-COPD group. The overall survival (OS) was compared and predictors of worse OS were analyzed. RESULTS: COPD was present in 54.7% of all SCLC patients. There were no differences in the clinical characteristics and treatment strategies between the COPD and non-COPD groups. OS (log-rank test, P=0.103) was not different between the COPD and non-COPD groups. In a multivariate analysis using a Cox regression model, extensive disease (ED) [hazard ratio (HR) =2.863; 95% CI: 1.787-4.587] and low forced expiratory volume in 1 second (FEV1) <80% (HR =1.854; 95% CI: 1.077-3.192) were independent risk factors for shorter survival. In a subgroup multivariate analysis, a FEV1 less than 80% (HR =5.631; P=0.018) was independently associated with poor OS in patients with ED. CONCLUSIONS: A low FEV1, not COPD, was a predicting factor for poor treatment outcomes in SCLC patients.
BACKGROUND: The impact of impaired pulmonary function on the clinical outcome of small cell lung cancer (SCLC) has not been examined. The objectives of this study were to compare the clinical characteristics and prognosis of SCLC patients with and without impaired pulmonary function and investigate predictors related to the pulmonary function of mortality in SCLC patients. METHODS: This is a retrospective multicenter study performed between January 2011 and December 2015. In all, 170 SCLC patients that were treated with chemotherapy and/or radiotherapy and had a pulmonary function test (PFT) were enrolled. Patients were divided into the chronic obstructive pulmonary disease (COPD) group and the non-COPD group. The overall survival (OS) was compared and predictors of worse OS were analyzed. RESULTS: COPD was present in 54.7% of all SCLC patients. There were no differences in the clinical characteristics and treatment strategies between the COPD and non-COPD groups. OS (log-rank test, P=0.103) was not different between the COPD and non-COPD groups. In a multivariate analysis using a Cox regression model, extensive disease (ED) [hazard ratio (HR) =2.863; 95% CI: 1.787-4.587] and low forced expiratory volume in 1 second (FEV1) <80% (HR =1.854; 95% CI: 1.077-3.192) were independent risk factors for shorter survival. In a subgroup multivariate analysis, a FEV1 less than 80% (HR =5.631; P=0.018) was independently associated with poor OS in patients with ED. CONCLUSIONS: A low FEV1, not COPD, was a predicting factor for poor treatment outcomes in SCLC patients.
Entities:
Keywords:
Forced expiratory volume (FEV); respiratory function tests; small cell lung cancer (SCLC)
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Carlos H Martinez; Susan Murray; R Graham Barr; Eugene Bleecker; Russell P Bowler; Stephanie A Christenson; Alejandro P Comellas; Christopher B Cooper; David Couper; Gerard J Criner; Jeffrey L Curtis; Mark T Dransfield; Nadia N Hansel; Eric A Hoffman; Richard E Kanner; Eric Kleerup; Jerry A Krishnan; Stephen C Lazarus; Nancy K Leidy; Wanda O'Neal; Fernando J Martinez; Robert Paine; Stephen I Rennard; Donald P Tashkin; Prescott G Woodruff; MeiLan K Han Journal: Ann Am Thorac Soc Date: 2017-05
Authors: Ramesh Gopal; George Starkschall; Susan L Tucker; James D Cox; Zhongxing Liao; Michael Hanus; Jason F Kelly; Craig W Stevens; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2003-05-01 Impact factor: 7.038
Authors: Ana Maria B Menezes; Rogelio Pérez-Padilla; Fernando César Wehrmeister; Maria Victorina Lopez-Varela; Adriana Muiño; Gonzalo Valdivia; Carmen Lisboa; José Roberto B Jardim; Maria Montes de Oca; Carlos Talamo; Renata Bielemann; Mariana Gazzotti; Ruy Laurenti; Bartolomé Celli; Cesar G Victora Journal: PLoS One Date: 2014-10-06 Impact factor: 3.240
Authors: Priscila Weber; Ana Maria Baptista Menezes; Helen Gonçalves; Rogelio Perez-Padilla; Deborah Jarvis; Paula Duarte de Oliveira; Fernando César Wehrmeister Journal: ERJ Open Res Date: 2020-08-25
Authors: Jinyoung Byun; Younghun Han; Quinn T Ostrom; Jacob Edelson; Kyle M Walsh; Rowland W Pettit; Melissa L Bondy; Rayjean J Hung; James D McKay; Christopher I Amos Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-03-26 Impact factor: 4.090
Authors: Georgia K Thomas; Cory R Trankle; Salvatore Carbone; Hayley Billingsley; Benjamin W Van Tassell; Ronald K Evans; Ryan Garten; Elisabeth Weiss; Antonio Abbate; Justin M Canada Journal: Lung Date: 2021-07-08 Impact factor: 3.777
Authors: I Re Heo; Ho Cheol Kim; Seung Jun Lee; Jung-Wan Yoo; Sunmi Ju; Yi Yeong Jeong; Jong Deog Lee; Yu Ji Cho; Jong Hwan Jeong; Manbong Heo; Seung Woo Jung; Tae Hoon Kim Journal: Thorac Cancer Date: 2021-08-01 Impact factor: 3.500